Literature DB >> 26942092

Comparison of naïve and central memory derived CD8+ effector cell engraftment fitness and function following adoptive transfer.

Xiuli Wang1, ChingLam W Wong1, Ryan Urak1, Ellie Taus1, Brenda Aguilar1, Wen-Chung Chang1, Armen Mardiros1, Lihua E Budde1, Christine E Brown1, Carolina Berger2, Stephen J Forman1, Michael C Jensen3.   

Abstract

Human CD8+ effector T cells derived from CD45RO+CD62L+ precursors enriched for central memory (TCM) precursors retain the capacity to engraft and reconstitute functional memory upon adoptive transfer, whereas effectors derived from CD45RO+CD62L- precursors enriched for effector memory precursors do not. Here we sought to compare the engraftment fitness and function of CD8+ effector T cells derived from CD45RA+CD62L+ precursors enriched for naïve and stem cell memory precursors (TN/SCM) with that of TCM. We found that cytotoxic T cells (CTLs) derived from TCM transcribed higher levels of CD28, FOS, INFγ, Eomesodermin (Eomes), and lower levels of BCL2L11, maintained higher levels of phosphorylated AKT, and displayed enhanced sensitivity to the proliferative and anti-apoptotic effects of γ-chain cytokines compared to CTLs derived from TN/SCM. Higher frequencies of CTLs derived from TCM retained CD28 expression and upon activation secreted higher levels of IL-2. In NOD/Scid IL-2RγCnull mice, CD8+ TCM derived CTLs engrafted to higher frequencies in response to human IL-15 and mounted robust proliferative responses to an immunostimulatory vaccine. Similarly, CD8+ TCM derived CD19CAR+ CTLs exhibited superior antitumor potency following adoptive transfer compared to their CD8+ TN/SCM derived counterparts. These studies support the use of TCM enriched cell products for adoptive therapy of cancer.

Entities:  

Keywords:  Antitumor activity; adoptive therapy; central memory T cell derived CTLs; engraftment fitness; naïve T cell derived CTLs

Year:  2015        PMID: 26942092      PMCID: PMC4760301          DOI: 10.1080/2162402X.2015.1072671

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  46 in total

1.  Memory CD44(int) CD8 T cells show increased proliferative responses and IFN-gamma production following antigenic challenge in vitro.

Authors:  M Pihlgren; C Arpin; T Walzer; M Tomkowiak; A Thomas; J Marvel; P M Dubois
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

2.  Apoptotic lymphocytes and CD34+ cells in cryopreserved cord blood detected by the fluorescent vital dye SYTO 16 and correlation with loss of L-selectin (CD62L) expression.

Authors:  R L Sparrow; H Komodromou; E Tippett; T Georgakopoulos; W Xu
Journal:  Bone Marrow Transplant       Date:  2006-07       Impact factor: 5.483

3.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A.

Authors:  F Pelloquin; J P Lamelin; G M Lenoir
Journal:  In Vitro Cell Dev Biol       Date:  1986-12

5.  The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.

Authors:  Anran Wang; Smita Chandran; Syed A Shah; Yu Chiu; Biman C Paria; Tamara Aghamolla; Melissa M Alvarez-Downing; Chyi-Chia Richard Lee; Sanmeet Singh; Thomas Li; Mark E Dudley; Nicholas P Restifo; Steven A Rosenberg; Udai S Kammula
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

6.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

7.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors:  Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

8.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

9.  T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

Authors:  Jiali Sun; Gianpietro Dotti; Leslie E Huye; Aaron E Foster; Barbara Savoldo; Maria M Gramatges; David M Spencer; Cliona M Rooney
Journal:  Mol Ther       Date:  2010-09-14       Impact factor: 11.454

Review 10.  Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation.

Authors:  Karen L Wood; Homer L Twigg; Andrea I Doseff
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  14 in total

Review 1.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.

Authors:  Lauren Suarez; Ruipeng Wang; Scott Carmer; Daniel Bednarik; Han Myint; Kristi Jones; Mathias Oelke
Journal:  Transfus Med Hemother       Date:  2020-11-16       Impact factor: 3.747

Review 3.  T memory stem cells in health and disease.

Authors:  Luca Gattinoni; Daniel E Speiser; Mathias Lichterfeld; Chiara Bonini
Journal:  Nat Med       Date:  2017-01-06       Impact factor: 53.440

Review 4.  Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.

Authors:  S Sengupta; G Mao; Z S Gokaslan; P Sampath
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

5.  Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.

Authors:  Junfang Yang; Jiaping He; Xian Zhang; Jingjing Li; Zhenguang Wang; Yongliang Zhang; Liyuan Qiu; Qionglu Wu; Zhe Sun; Xun Ye; Wenjie Yin; Wei Cao; Lianjun Shen; Martina Sersch; Peihua Lu
Journal:  Blood Cancer J       Date:  2022-07-07       Impact factor: 9.812

6.  Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.

Authors:  Cheng Zhang; Jiaping He; Li Liu; Jishi Wang; Sanbin Wang; Ligen Liu; Jian Ge; Lei Gao; Li Gao; Peiyan Kong; Yao Liu; Jia Liu; Yu Han; Yongliang Zhang; Zhe Sun; Xun Ye; Wenjie Yin; Martina Sersch; Lianjun Shen; Wei William Cao; Xi Zhang
Journal:  Blood Cancer J       Date:  2022-06-24       Impact factor: 9.812

7.  Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Authors:  J Joseph Melenhorst; Michael C Milone; Saba Ghassemi; Selene Nunez-Cruz; Roddy S O'Connor; Joseph A Fraietta; Prachi R Patel; John Scholler; David M Barrett; Stefan M Lundh; Megan M Davis; Felipe Bedoya; Changfeng Zhang; John Leferovich; Simon F Lacey; Bruce L Levine; Stephan A Grupp; Carl H June
Journal:  Cancer Immunol Res       Date:  2018-07-20       Impact factor: 11.151

8.  Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.

Authors:  Stephen J Forman; Xiuli Wang; Ryan Urak; Miriam Walter; Laura Lim; ChingLam W Wong; Lihua E Budde; Sandra Thomas
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

9.  Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Authors:  Caroline Boudousquie; Giovanna Bossi; Jacob M Hurst; Karolina A Rygiel; Bent K Jakobsen; Namir J Hassan
Journal:  Immunology       Date:  2017-08-02       Impact factor: 7.397

Review 10.  Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success.

Authors:  Ilaria M Michelozzi; Efstratios Kirtsios; Alice Giustacchini
Journal:  Cancers (Basel)       Date:  2021-06-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.